Table 1:

Baseline characteristics and safety profile of participants in the efficacy, safety only and combined cohort.

	Efficacy cohort N=12	Safety only cohort N=10	Combined cohort N=22
Age (years)	37.4±14.1	45.2±11.1	40.9±13.2
Gender	10 Females, 2 males	10 Females	20 Females, 2 males
Race
White	11 (92%)	10 (100%)	21 (95%)
Black	1 (8%)	0	1 (4%)
Weight (kg)	79.9±23.6	66.4±7.9	74.2±19.5
Height (cm)	167.8±11.9	165.5±4.8	166.8±9.4
BMI (kg/m2)	28.1±6.9	24.2±2.5	26.4±5.7
Systolic blood pressure (mmHg)	122±11	121±16	122±13
Diastolic blood pressure (mmHg)	73±8	72±13	73±10
Type of SGLT2i
Canagliflozin	9 (75%)	6 (60%)	15 (68%)
Empagliflozin	3 (25%)	3 (30%)	6 (27%)
Dapagliflozin	0	1 (10%)	1 (4%)
Number of patients taking insulin	10 (83.3%)	7 (70%)	17 (77%)
Number of patients taking metformin	10 (83.3%)	8 (80%)	18 (82%)
Number of patients taking GLP-1 agonists	0	3 (30%)	3 (14%)
Number of patients taking DPP-4 inhibitors	1 (8%)	0	1 (4%)
Number of patients taking thiazolidinedione	0	1 (10%)	1 (4%)
Patients who encountered adverse events	4 (33%)	3 (30%)	7 (32%)
Patients who discontinued SGLT2i due to adverse events	1 (8%)	2 (20%)	3 (14%)
Duration of SGLT2i use before discontinuing* (months)	5.8	0.6±0.5	2.3±3.0
Adverse events
Urinary tract infection	0	1 (10%)	1 (4%)
Fungal infections	1 (8%)	0	1 (4%)
Diabetes ketoacidosis	1 (8%)	0	1 (4%)
Pancreatitis	0	1 (10%)	1 (4%)
Arm or foot pain	1 (8%)	1 (10%)	2 (9%)
Hypoglycemia	1 (8%)	0	1 (4%)

Data are shown as N (%) or mean±SD.

^*Among patients who discontinued due to adverse event.